Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cureus ; 15(11): e48666, 2023 Nov.
Article in English | MEDLINE | ID: mdl-38090435

ABSTRACT

Horner's syndrome has been identified as an adverse outcome associated with the administration of epidural analgesia during labor. This syndrome is attributed to the upward spread of the local anesthetic, which may extend toward the superior cervical sympathetic chain. This process could disrupt the sympathetic pathways supplying the facial and ocular areas. We describe a case of a 26-year-old primigravid female with transient isolated Horner's syndrome following dural puncture epidural analgesia during labor.

2.
J Stroke Cerebrovasc Dis ; 31(7): 106489, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35489182

ABSTRACT

Intracerebral hemorrhage (ICH) is a devastating subtype of stroke associated with high morbidity and mortality that is considered a medical emergency, mainly managed with adequate blood pressure control and creating a favorable hemostatic condition. However, to date, none of the randomized clinical trials have led to an effective treatment for ICH. It is vital to better understand the mechanisms underlying brain injury to effectively decrease ICH-associated morbidity and mortality. It is well known that initial hematoma formation and its expansion have detrimental consequences. The literature has recently focused on other pathological processes, including oxidative stress, neuroinflammation, blood-brain barrier disruption, edema formation, and neurotoxicity, that constitute secondary brain injury. Since conventional management has failed to improve clinical outcomes significantly, various neuroprotective therapies are tested in preclinical and clinical settings. Unlike intravenous administration, intranasal insulin can reach a higher concentration in the cerebrospinal fluid without causing systemic side effects. Intranasal insulin delivery has been introduced as a novel neuroprotective agent for certain neurological diseases, including ischemic stroke, subarachnoid hemorrhage, and traumatic brain injury. Since there is an overlap of mechanisms causing neuroinflammation in these neurological diseases and ICH, we believe that preclinical studies testing the role of intranasal insulin therapy in ICH are warranted.


Subject(s)
Brain Injuries , Nervous System Diseases , Neuroprotective Agents , Cerebral Hemorrhage/complications , Hematoma/drug therapy , Humans , Insulin , Neuroprotective Agents/adverse effects
3.
J Med Life ; 12(3): 260-265, 2019.
Article in English | MEDLINE | ID: mdl-31666828

ABSTRACT

Lower back pain is one of the leading causes of disability in the world. The aim of this study was to evaluate the effect of supplementation of dexmedetomidine and neostigmine with lidocaine 1.5% and triamcinolone for epidural block in increasing the duration of analgesia among patients suffering from chronic low back pain. In this double-blind, randomized clinical trial, 33 patients with chronic low back pain were included in three groups of 11 patients for epidural blockage. Triamcinolone (40 mg/ml) was added to lidocaine 1.5% solution (2 cc/segment) for all three groups. In group N, neostigmine was used at a dose of 1 mg (mg), followed by group D (dexmedetomidine 35 µg [0.5 µg/kg]), and grou [ND (neostigmine 0.5 mg, and 35 µg dexmedetomidine, all of which were added to the triamcinolone and lidocaine solution in each group. Medications were injected into the epidural space using an interlaminar approach. Subsequently, scores of pain and duration of analgesia were recorded in questionnaires and analysed using SPSS version 23. One month after the injections, pain scores recorded in the N group were 7.6±1.4, followed by 5.88±1.2 in group D and 5.42 ±1.1 in group ND. Therefore, the pain scores were significantly higher in the neostigmine group than the other two groups (p = 0.02), but no significant difference was found between the two groups that received dexmedetomidine and a combination of dexmedetomidine + neostigmine. Three months after the injections, there was a significant difference in pain scores between the two groups (P = 0.01). Both neostigmine and dexmedetomidine were capable of reducing the pain of patients with chronic low back pain after epidural block. However, neostigmine's impact is lower compared to dexmedetomidine. The combination of the two drugs also reduced the pain scores of the patients after the intervention.


Subject(s)
Analgesia, Epidural , Chronic Pain/drug therapy , Dexmedetomidine/therapeutic use , Lidocaine/therapeutic use , Low Back Pain/drug therapy , Neostigmine/therapeutic use , Triamcinolone/therapeutic use , Adult , Blood Pressure/drug effects , Chronic Pain/physiopathology , Dexmedetomidine/pharmacology , Double-Blind Method , Female , Heart Rate/drug effects , Humans , Lidocaine/pharmacology , Low Back Pain/physiopathology , Male , Neostigmine/pharmacology , Oxygen/metabolism , Pain Management , Triamcinolone/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...